Michael Sweeney is an associate in the Los Angeles office of Latham & Watkins and a member of the firm’s Corporate Department and Healthcare & Life Sciences Practice.

Mr. Sweeney represents companies in the biotechnology and life sciences industries. He has experience negotiating technology and commercial agreements, including patent and software licenses, technology transfer, manufacturing and supply, collaboration, and joint venture agreements.

Mr. Sweeney has been involved in the strategic development of IP portfolios in a broad array of life sciences fields, including:

  • Computational biology
  • Immunology
  • CRISPR and bioengineering
  • Genetics and genomics
  • Diagnostics
  • Nanobiotechnology
  • Cancer therapeutics

Mr. Sweeney also represents buyers, sellers, investment banks, and other financial institutions in performing intellectual property due diligence for private and public financings and mergers and acquisitions.

Mr. Sweeney is registered to practice before the United States Patent and Trademark Office. Prior to joining Latham, Mr. Sweeney developed substantial experience in patent prosecution and counselling at another multinational firm. He has represented established technology veterans and emerging companies in protecting and commercializing their intellectual property portfolios.

Thought Leadership

  • Co-Author, “Agricultural Bioengineering: Navigating the Regulatory Terrain,” Food Online and Feed and Grain, 2018
  • Co-Author, “How the Fanapt Product Label Established Infringement of Personalized Treatment Claims,” Nat. Law Review, 2018
  • Author, “Correcting Bayh-Dole’s Inefficiencies for the Taxpayer,” 10 NW. J. TECH. AND INTELL. PROP., 295, 2012

Bar Qualification

  • California
  • US Patent and Trademark Office


  • M.Sc. in Biomedical Engineering, Columbia University
  • J.D., Northwestern University School of Law
  • B.A. in Law and Society, University of California, Santa Barbara

Languages Spoken

  • English